Effects of censoring on the confirmed disability worsening in multiple sclerosis clinical trials

Takeaway

  • Using an observed rate multiple imputation (ORMI) approach on confirmed disability worsening (CDW) risk factors minimized bias and provided the most accurate treatment effect estimate for the CDW endpoint.

Why this matters

    Confirmed disability worsening is a key endpoint for clinical trials of individuals with relapsing-remitting multiple sclerosis (RRMS). The results of this study recommend incorporating estimates of CDW risk into future clinical trials of multiple sclerosis (MS) which are consistent with observed trial data.